Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-11-11 / Prostate 2021 Nov;Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial Carcinoma /von 2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-03-29 / Front Immunol 2021;12:641307High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-10-26 / Front Oncol 2020;10:536700Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
/in Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-03-01 / J Immunother Cancer 2020 03;8(1)Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de